The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. 1/1000 when using colorimetric substrates such as BCIP/NBT - 1/5000 when using chemiluminescent substrates. Note: EDTA/EGTA treatment of tissues or lysates is required to see latent zymogen.
Use at an assay dependent concentration. PubMed: 21791558
Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. Could also be a critical factor in the exacerbation of neurodegeneration in Alzheimer disease. Cleaves aggrecan at the '392-Glu- -Ala-393' site.
Expressed in brain, lung and heart. Expressed at very low level in placenta and skeletal muscles.
The spacer domain and the TSP type-1 domains are important for a tight interaction with the extracellular matrix. The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
The precursor is cleaved by a furin endopeptidase.
Secreted > extracellular space > extracellular matrix.
Anti-ADAMTS4 antibody - Carboxyterminal end (ab28285) 使用論文
This product has been referenced in:
Zhou Z et al. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature532:122-6 (2016).
Read more (PubMed: 27027284) »
Wainwright SD et al. ADAMTS-4_v1 is a splice variant of ADAMTS-4 that is expressed as a protein in human synovium and cleaves aggrecan at the interglobular domain. Arthritis Rheum65:2866-75 (2013).
Read more (PubMed: 23897278) »